Catalent, a global CDMO headquartered in Somerset, NJ, plans to cut approximately 300 employees in its Biologics and Pharma and Consumer Health segments as part of its restructuring plans to reduce costs and consolidate facilities.

Employee and non-employee restructuring charges associated with Catalent’s plans to reduce costs, consolidate facilities, and optimize its infrastructure across the organization were $30 million in the company’s fiscal second quarter and $17 million three months ended December 31, 2023.
 
On February 5, Catalent announced it had entered into a merger agreement under which Novo Holdings, an investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation, will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion. The transaction would boost Semaglutide supply, which Novo Nordisk markets as Ozempic for type 2 diabetes and Wegovy for weight management.
 
Of Catalent’s more than 50 global sites, Novo Holdings intends to sell three Catalent fill-finish sites and related assets acquired in the merger to Novo Nordisk, in which Novo Holdings has a controlling interest, shortly after the closing of the merger.
 
Catalent is a global provider of drug development, manufacturing, and delivery technologies for pharmaceuticals, biologics, and consumer health products, and has approximatley 14,000 employees.

Read More: Catalent 2Q Fiscal 2024 Results